James L. Abbruzzese
Duke University
623 Papers
9.4K Citations
James L. Abbruzzese is an academic researcher from Duke University. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 117, co-authored 609 publications. Previous affiliations of James L. Abbruzzese include Mansoura University & University of California, San Francisco.
Chat about Author
Papers
Therapeutic applications of NSAIDS in cancer: special emphasis on tolfenamic acid.
Riyaz Basha,C. T. Baker,C. T. Baker,Umesh T Sankpal PhD,Sarfraz Ahmad,Stephen Safe,James L. Abbruzzese,Maen Abdelrahim +7 more
TL;DR: A summary on the potential benefits of NSAIDs in a variety of human cancers with more emphasis on tolfenamic acid is provided.
44
Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death
Tadashi Uwagawa,Zhongkui Li,Zhe Chang,Zhe Chang,Qianghua Xia,Qianghua Xia,Bailu Peng,Guido M. Sclabas,Satoshi Ishiyama,Mien Chie Hung,Mien Chie Hung,Douglas B. Evans,James L. Abbruzzese,Paul J. Chiao,Paul J. Chiao +14 more
TL;DR: The authors studied the role of FUT‐175, a synthetic serine protease inhibitor, in the inhibition of NF‐κB activation and the induction of apoptotic responses to identify an effective therapeutic agent for pancreatic cancer.
44
•Journal Article
Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines.
Bohuslav Melichar,Gabriella Ferrandina,Claire F. Verschraegen,Amy E. Loercher,James L. Abbruzzese,Ralph S. Freedman +5 more
TL;DR: An immune modulatory role might also be suggested for PB because it resulted in increased ovarian tumor cell expression of human leukocyte antigen class I and the cluster of differentiation molecule CD58, whereas transforming growth factor-beta2 expression was decreased.
44
Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma.
Richard Pazdur,Enrique Diaz-Canton,W P Ballard,J E Bradof,S Graham,Susan G. Arbuck,James L. Abbruzzese,Rodger J. Winn +7 more
TL;DR: At the dose and schedule used in this trial, 9-AC lacked antitumor activity in metastatic colorectal cancer, and infusion schedules of longer duration are currently being investigated in this disease.
44
Genetic and Nongenetic Covariates of Pain Severity in Patients with Adenocarcinoma of the Pancreas: Assessing the Influence of Cytokine Genes
Cielito C. Reyes-Gibby,Sanjay Shete,Sriram Yennurajalingam,Marsha L. Frazier,Eduardo Bruera,Razelle Kurzrock,Christopher H. Crane,James L. Abbruzzese,Douglas B. Evans,Margaret R. Spitz +9 more
TL;DR: Preliminary evidence of the role of IL-8 in the severity of pain in pancreatic cancer patients is provided, with carriers of TT and AT genotypes having more than a threefold risk for severe pain relative to the AA genotypes.
44